why choose us

First received: May 09, 2023

Clinical Trial: A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRP?-CD47 Pathway, in Solid or Hematological Tumors

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Advanced Solid Tumor

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Open-label, Multi-center, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of HCB101 in Subjects With Advanced Solid Tumors or Relapsed and

Brief Summary: The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed or refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.

Read more